COP vs SPRO · P/E 19, rev $58.94B vs P/E 9.6, rev $48.0M
ConocoPhillips (COP) versus Spero Therapeutics Inc (SPRO) — a side-by-side from cached financials, not a winner call.
ConocoPhillips (COP) is a oil & gas e&p company listed on NYSE. It is led by Ryan Lance.
Spero Therapeutics Inc (SPRO) is a biotechnology company listed on NASDAQ.
Latest reported COP revenue for 2025-12-31 was $58.94B. Net income was $7.99B. Revenue was up 7.7% from 2024-12-31 to 2025-12-31. COP currently screens at market cap $135.49B and trailing P/E 18.8.
Latest reported SPRO revenue for 2024-12-31 was $48.0M. Net income was -$68.6M. Revenue was down 53.8% from 2023-12-31 to 2024-12-31. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.
COP currently screens at market cap $135.49B and trailing P/E 18.8. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.
Not investment advice. Open the COP and SPRO stock pages for the full models.
Not investment advice.